CloudCath

About CloudCath

CloudCath, founded in 2017 by Aly ElBadry and Eric Yu, is a medical device company focused on remote patient monitoring for catheter-based treatments. The founders, both graduates of the Stanford Biodesign Innovation Program, were driven by a passion for applying technology to the shift from traditional in-center medical facilities to home-based care. This led to the creation of a platform aimed at providing data-driven remote management to improve patient outcomes.

The company operates in the end-stage renal disease (ESRD) market, specifically targeting patients undergoing peritoneal dialysis (PD) at home. Its business model centers on providing healthcare providers and clinics with a remote monitoring system that allows for proactive patient care. This is particularly timely, given a 2019 White House executive order aimed at increasing the use of at-home dialysis. CloudCath has raised a total of $12 million in funding, with its latest Series A round in February 2020. A significant milestone was achieved in February 2022, when the company received FDA 510(k) clearance for its monitoring system, paving the way for a limited commercial launch in the U.S.

CloudCath's flagship product, the CloudCath System, is an IoT-based platform that remotely monitors patients for early signs of complications, such as infections. The system integrates seamlessly into a patient's daily PD equipment and uses advanced optical sensors to analyze the turbidity of drained dialysate fluid on every cycle. This process replaces the subjective and often late-detection "newspaper test," where patients visually inspect fluid clarity. By detecting subtle changes in the fluid, the device's algorithms can identify potential issues days before physical symptoms appear. The data is transmitted in real-time to a cloud-based platform, which automatically notifies clinicians of any deviations, enabling early intervention. This approach is designed to reduce infection-driven hospitalizations, improve the quality of life for PD patients, and build a stronger connection between patients and their care teams.